- Home
- KOPN vs MNPR Comparison
KOPN vs MNPR Comparison
Compare KOPN & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOPN
- MNPR
- Stock Information
- Founded
- KOPN 1984
- MNPR 2014
- Country
- KOPN United States
- MNPR United States
- Employees
- KOPN N/A
- MNPR N/A
- Industry
- KOPN Semiconductors
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- KOPN Technology
- MNPR Health Care
- Exchange
- KOPN Nasdaq
- MNPR Nasdaq
- Market Cap
- KOPN 255.1M
- MNPR 209.3M
- IPO Year
- KOPN 1992
- MNPR 2019
- Fundamental
- Price
- KOPN $1.58
- MNPR $36.25
- Analyst Decision
- KOPN Strong Buy
- MNPR Strong Buy
- Analyst Count
- KOPN 3
- MNPR 6
- Target Price
- KOPN $2.58
- MNPR $59.60
- AVG Volume (30 Days)
- KOPN 3.1M
- MNPR 55.8K
- Earning Date
- KOPN 08-07-2025
- MNPR 08-08-2025
- Dividend Yield
- KOPN N/A
- MNPR N/A
- EPS Growth
- KOPN N/A
- MNPR N/A
- EPS
- KOPN N/A
- MNPR N/A
- Revenue
- KOPN $50,841,018.00
- MNPR N/A
- Revenue This Year
- KOPN $8.02
- MNPR N/A
- Revenue Next Year
- KOPN $20.99
- MNPR N/A
- P/E Ratio
- KOPN N/A
- MNPR N/A
- Revenue Growth
- KOPN 28.16
- MNPR N/A
- 52 Week Low
- KOPN $0.56
- MNPR $1.72
- 52 Week High
- KOPN $2.17
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- KOPN 55.40
- MNPR 54.35
- Support Level
- KOPN $1.44
- MNPR $31.84
- Resistance Level
- KOPN $1.64
- MNPR $36.20
- Average True Range (ATR)
- KOPN 0.09
- MNPR 2.09
- MACD
- KOPN -0.02
- MNPR 0.41
- Stochastic Oscillator
- KOPN 53.85
- MNPR 100.00
About KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.